AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention
- 1 December 2008
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Vaccines
- Vol. 7 (10), 1465-1473
- https://doi.org/10.1586/14760584.7.10.1465
Abstract
Persistent infection with oncogenic human papillomavirus (HPV)-16 and -18 accounts for over 70% of all cases of cervical cancer. Vaccination against these HPV types has become a reality. This article discusses the latest data available for Cervarix (GlaxoSmithKline Biologicals), an AS04-adjuvanted HPV-16/18 vaccine, and considers immunological factors important in vaccine effectiveness. High and sustained HPV-16 and -18 antibody levels have now been observed together with 100% vaccine efficacy in preventing HPV-16/18-related persistent infections and cervical intraepithelial neoplasia grade 2 and above, up to 6.4 years after first vaccination. Significant crossprotection against incident and persistent infection has been observed, notably against HPV-45, the third most prevalent HPV type in cervical cancer. An integrated safety summary of Phase II/III trials has shown that GlaxoSmithKline's HPV-16/18 AS04-adjuvanted vaccine is generally safe. Further studies will reveal the full duration and extent of the immune response and protection induced by Cervarix in broad populations and age ranges of women.Keywords
This publication has 41 references indexed in Scilit:
- Impact of vaccination with Cervarix™ on subsequent HPV-16/18 infection and cervical disease in women 15–25 years of ageGynecologic Oncology, 2008
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- EUROGIN 2007 roadmap—ConclusionVaccine, 2008
- Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of InhibitionJournal of Virology, 2007
- 55. HIGH EFFICACY OF A HPV-16/18 L1 VIRUS-LIKE PARTICLE (VLP) VACCINE ADJUVANTED WITH AS04 AGAINST CIN2+ CAUSED BY HPV-16/18 INFECTION IN A BROAD POPULATION OF YOUNG WOMENSexual Health, 2007
- Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and PreventionJNCI Journal of the National Cancer Institute, 2006
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- The Rising Incidence of Adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States—A 24-Year Population-Based StudyGynecologic Oncology, 2000
- Comparison of Human Papillomavirus Types 16, 18, and 6 Capsid Antibody Responses Following Incident InfectionThe Journal of Infectious Diseases, 2000